News Sentiment

ALT sentiment intelligence

Altimmune Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.87 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.9% over one week, +6.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -5.9% Price reacting lower
Trend fit Trend inactive 6.3% over four weeks
Fair value -48.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 35
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 12
Stock Titan 7
simplywall.st 5
www.marketscreener.com 4
Insider Monkey 3
Stocktwits 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 15
Analyst action 7
Guidance 2
Regulatory and legal 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stocktwits Direct company coverage

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

Despite Altimmune (ALT) stock experiencing a 45% drop over the last year, Wall Street analysts are projecting a significant upside, with an average 12-month price target of $18, suggesting a potential 495% increase from its current $3.02 trading price. Nine out of eleven analysts

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jul 2026 18:41
Source
Stocktwits
Longevity.Technology Direct company coverage

Altimmune gets analyst boost as MASH data grow

Altimmune received an "Outperform" rating and a $10 price target from Leerink, a specialized healthcare investment bank, due to growing confidence in its drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Clinical data from the IMPACT Phase 2b trial sho

Tone
Positive 72/100
Event
Analyst action
Published
09 Jul 2026 16:05
Source
Longevity.Technology
TradingView Direct company coverage

Altimmune, Inc. Actuals & Estimates (DUS:3G0)

This article provides actual financial data and analyst estimates for Altimmune, Inc. (DUS:3G0), including income statements, balance sheets, and cash flow information. It details financial performance, future price forecasts from analysts, historical stock prices, and upcoming e

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 04:39
Source
TradingView
TradingView Direct company coverage

ETFs Investing in Altimmune, Inc. Stocks

This article lists various ETFs that hold Altimmune, Inc. (0A4C) stocks, providing detailed information about each fund. The data includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volum

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 04:40
Source
TradingView
www.marketscreener.com Direct company coverage

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark

Altimmune, Inc. (NasdaqGM:ALT) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including presentations at a healthcare conference and data releases on its lead product candidate, pem

Tone
Negative 19/100
Event
Market update
Published
29 Jun 2026 16:56
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark

Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focused on liver disease therapies, has been removed from the Russell 2500 Growth Benchmark. The company's lead product candidate, pemvidutide, is in development for conditions such as MASH, AUD, and

Tone
Negative 29/100
Event
Market update
Published
29 Jun 2026 15:30
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index

Altimmune, Inc. (NasdaqGM: ALT) has been added to the Russell Microcap Value Benchmark Index. This announcement was made on June 29, 2026, and is significant for the late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, includin

Tone
Positive 69/100
Event
Market update
Published
29 Jun 2026 13:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark

Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focusing on liver diseases, has been removed from the Russell 2000 Growth Benchmark. Despite this drop, the company continues to develop its lead product candidate, pemvidutide, for treatments like m

Tone
Negative 28/100
Event
Market update
Published
29 Jun 2026 10:40
Source
www.marketscreener.com
The National Law Review Direct company coverage

ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT) for alleged federal securities law violations. The lawsuit claims Altimmune made false and misleading statements regarding its Pemvidutide MASH trial and downplayed its f

Tone
Negative 18/100
Event
Regulatory and legal
Published
29 Jun 2026 07:40
Source
The National Law Review
TradingView Direct company coverage

Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT

This article focuses on the enterprise value to revenue forward for Altimmune, Inc. (NASDAQ:ALT). It is likely a financial data point or metric provided by TradingView, indicating a key valuation measure for the biotechnology company. The content appears to be a stub or data-focu

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Altimmune, Inc. – SWB:3G0

This article provides financial information for Altimmune, Inc. (SWB:3G0), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section of a larger financial data report, indicating that the value for this metric is available for differe

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Altimmune, Inc. – SWB:3G0

The provided content is a financial data page for Altimmune, Inc. (SWB:3G0) on TradingView, focusing on its enterprise value to revenue forward metric. The page includes general company information, market data from the Stuttgart Stock Exchange, and various navigation elements co

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 12:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT

This page provides financial information for Altimmune, Inc. (NASDAQ: ALT), focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades, and the content primarily serves as a data display from TradingView sourced from ICE Data Services

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Altimmune, Inc. – NASDAQ:ALT

This article provides the "Price to sales forward" financial metric for Altimmune, Inc. (NASDAQ: ALT). It appears to be a stub or a section of a larger financial data report, indicating the value and change of this specific financial ratio for the company. The content primarily f

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Altimmune, Inc. – SWB:3G0

This article provides financial information for Altimmune, Inc. (SWB:3G0) on TradingView, specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed and no trades were made at the time of publication, indicating a static financial snaps

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Altimmune, Inc. – BMV:ALT1

This article focuses on the "Price to earnings forward" metric for Altimmune, Inc. (BMV:ALT1). The content includes financial overview elements and market data references. It appears to be a stub or a section from a larger financial analysis platform.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:09
Source
TradingView
Yahoo! Finance Canada Direct company coverage

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

The drug and biotech sector is recovering from a difficult period, driven by strong M&A activity, pipeline successes, and innovation. The Zacks Medical-Drugs industry, which includes small and medium-sized drug companies, shows promising trends, with Indivior Pharmaceuticals, Aur

Tone
Positive 67/100
Event
Guidance
Published
26 Jun 2026 03:59
Source
Yahoo! Finance Canada
TradingView Direct company coverage

Enterprise value to EBITDA forward of Altimmune, Inc. – BMV:ALT1

This article displays financial data, specifically the Enterprise Value to EBITDA forward, for Altimmune, Inc. (BMV:ALT1). It indicates that the market for this stock was closed with no trades recorded. The content is presented within the TradingView platform interface, emphasizi

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:41
Source
TradingView
TradingView Direct company coverage

A2N5Z6 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Altimmune, Inc. (A2N5Z6) stock, including analyst price targets and ratings. It details recent stock performance, future earnings expectations, and various financial metrics for the company. The current price is 2.6000 EUR, with a 1-year price

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 16:41
Source
TradingView
Insider Monkey Direct company coverage

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

Altimmune, Inc. (NASDAQ:ALT) remains a "Buy" according to H.C. Wainwright, despite a price target reduction from $25 to $20 due to dilution from recent equity offerings. The company's strengthened funding position and progress in its MASH program are viewed positively. Recent Pha

Tone
Positive 61/100
Event
Analyst action
Published
24 Jun 2026 14:09
Source
Insider Monkey
TradingKey Direct company coverage

Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Altimmune Inc (ALT) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus "Buy" rating for ALT, with an average price target of $20.00 and a potential upside of 543.13%. The company's expected revenue

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:39
Source
TradingKey
The Globe and Mail Direct company coverage

Altimmune Relocates Corporate Headquarters to Morristown, New Jersey

Altimmune, Inc. announced its decision to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year, signing a five-year lease. This strategic move aims to leverage Morristown's dense biopharmaceutical industry presence, enhance t

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 04:09
Source
The Globe and Mail
The Business Journals Direct company coverage

Altimmune moving headquarters from Gaithersburg to New Jersey

Altimmune is relocating its headquarters from Gaithersburg, Maryland, to New Jersey, citing cost efficiencies and better access to top-tier talent

Tone
Positive 61/100
Event
Market update
Published
17 Jun 2026 12:11
Source
The Business Journals
Insider Monkey Direct company coverage

Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data

Altimmune (NASDAQ:ALT) is advancing its lead drug candidate, pemvidutide, for MASH, a serious liver disease. Recent 48-week data from its IMPACT Phase 2b study showed improvements in metabolic health measures, including triglycerides and cholesterol, and the company plans to star

Tone
Positive 73/100
Event
Market update
Published
17 Jun 2026 11:16
Source
Insider Monkey